Clopidogrel for Proteinuria Reduction in Focal Segmental Glomerulosclerosis: Phase 2 Trial Design
Authors:
Open Access
- 3 November 2023
- journal article
- editorial
- Published by Elsevier in Kidney International Reports
- Vol. 9 (2) , 478-481
Abstract
No abstract availableKeywords
Funding Information
- Catalyst Biosciences
- Otsuka America
- Medizinische Universität Wien
- American Society of Nephrology
This publication has 8 references indexed in Scilit:
- Computational drug repositioning of clopidogrel as a novel therapeutic option for focal segmental glomerulosclerosisTranslational Research, 2023
- P2Y12 inhibitor clopidogrel inhibits renal fibrosis by blocking macrophage-to-myofibroblast transitionMolecular Therapy, 2022
- Antiplatelet agents for chronic kidney diseaseCochrane Database of Systematic Reviews, 2022
- Interventions for focal segmental glomerulosclerosis in adultsCochrane Database of Systematic Reviews, 2022
- Informing single-arm clinical trials with external controlsNature Reviews Drug Discovery, 2020
- A systems pharmacology workflow with experimental validation to assess the potential of anakinra for treatment of focal and segmental glomerulosclerosisPLOS ONE, 2019
- DUET: A Phase 2 Study Evaluating the Efficacy and Safety of Sparsentan in Patients with FSGSJournal of the American Society of Nephrology, 2018
- “Threshold‐crossing”: A Useful Way to Establish the Counterfactual in Clinical Trials?Clinical Pharmacology & Therapeutics, 2016